311 related articles for article (PubMed ID: 10122052)
1. The 1992 biotechnology agenda: a message for candidates Bush and Clinton.
Duzan SA
Healthspan; 1992 Sep; 9(8):12-5. PubMed ID: 10122052
[No Abstract] [Full Text] [Related]
2. Surprise US election results may boost biotech.
Fox JL
Nat Biotechnol; 2002 Dec; 20(12):1176. PubMed ID: 12454655
[No Abstract] [Full Text] [Related]
3. Research interactions between industry and academia: a corporate perspective.
Citron P
Physiologist; 1996 Jun; 39(3):81, 90-2. PubMed ID: 16764116
[No Abstract] [Full Text] [Related]
4. FDA launches priority vouchers for neglected-disease drugs.
Waltz E
Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849
[No Abstract] [Full Text] [Related]
5. Experimental use and the Orphan Drug Act: a biotechnology conundrum.
Koivuniemi PJ
Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930
[No Abstract] [Full Text] [Related]
6. Supporting the work of lesser geniuses: an argument for removing obstructions to human embryonic stem cell research.
Hazuka CD
Univ Miami Law Rev; 2002 Oct; 57(1):157-220. PubMed ID: 15156896
[No Abstract] [Full Text] [Related]
7. Genetic patents: gatekeeper to the promised cures.
Westin LP
Thomas Jefferson Law Rev; 2002; 25(1):271-99. PubMed ID: 15164741
[No Abstract] [Full Text] [Related]
8. Reexamining the research exemption.
Flores MA; Campbell C
Nat Biotechnol; 2005 Jun; 23(6):659-61. PubMed ID: 15940230
[No Abstract] [Full Text] [Related]
9. Realizing two-tiered innovation policy through drug regulation.
Ridgway WE
Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
[No Abstract] [Full Text] [Related]
10. Patenting race.
Kahn J
Nat Biotechnol; 2006 Nov; 24(11):1349-51. PubMed ID: 17093476
[TBL] [Abstract][Full Text] [Related]
11. Regulation of biotechnology by executive orders: questions about constitutionality, legality and overall fairness to the American public.
Cuomo P
J Biolaw Bus; 2005; 8(2):30-42. PubMed ID: 16538813
[TBL] [Abstract][Full Text] [Related]
12. The application of the patent laws to the drug approval process.
Coggio BD; Cerrito FD
Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669
[No Abstract] [Full Text] [Related]
13. Medical innovation meets healthcare reform.
White JH
Health Prog; 1994; 75(6):14-6, 32. PubMed ID: 10135162
[No Abstract] [Full Text] [Related]
14. The CREATE Act: increasing costs associated with the biotech industry?
Mills AE; Chen DT; Gillon JJ; Tereskerz PM
Nat Biotechnol; 2006 Jul; 24(7):785-6. PubMed ID: 16841059
[TBL] [Abstract][Full Text] [Related]
15. Biotech as Bush bows out.
Lorenzo A
Nat Biotechnol; 2008 Jan; 26(1):15-8. PubMed ID: 18183006
[No Abstract] [Full Text] [Related]
16. Razing the tollbooths. A call for restricting patents on basic biomedical research.
Stix G
Sci Am; 2003 Apr; 288(4):37. PubMed ID: 12661312
[No Abstract] [Full Text] [Related]
17. Owning the secret of life: biotechnology and property rights revisited.
Yelpaala K
McGeorge Law Rev; 2000; 32(1):111-219. PubMed ID: 15709267
[No Abstract] [Full Text] [Related]
18. Robert Stoll. Interview by Charlotte Harrison.
Stoll R
Nat Rev Drug Discov; 2009 Dec; 8(12):926. PubMed ID: 19949397
[No Abstract] [Full Text] [Related]
19. Nontraditional publications and their effect on patentable inventions.
Garabedian TE
Nat Biotechnol; 2002 Apr; 20(4):401-2. PubMed ID: 11923849
[No Abstract] [Full Text] [Related]
20. Companies balk at California's patent rules for stem cell research.
Keim B
Nat Med; 2007 Jan; 13(1):6. PubMed ID: 17206112
[No Abstract] [Full Text] [Related]
[Next] [New Search]
